Molecular Interaction of Human Brain Acetylcholinesterase with a Natural Inhibitor Huperzine-B: An Enzoinformatics Approach

被引:28
作者
Alam, Aftab [1 ]
Shaikh, Sibhghatulla [2 ]
Ahmad, Syed S. [1 ]
Ansari, Mohammad A. [2 ]
Shakil, Shahnawaz [1 ,3 ]
Rizvi, Syed M. D. [2 ]
Shakil, Shazi [1 ]
Imran, Mohammad [2 ]
Haneef, Mohammad [1 ]
Abuzenadah, Adel M. [4 ]
Kamal, Mohammad A. [4 ]
机构
[1] Integral Univ, Dept Bioengn, Lucknow 226026, Uttar Pradesh, India
[2] Integral Univ, Dept Biosci, Lucknow 226026, Uttar Pradesh, India
[3] Cardinal Hlth 7000, Dublin, OH 43017 USA
[4] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah 21589, Saudi Arabia
关键词
Acetylcholinesterase; autodock4.2; hydrophobic interactions; catalytic site; ALZHEIMERS-DISEASE; DOCKING;
D O I
10.2174/18715273113126660163
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
The present study emphasizes the molecular interactions between human brain acetylcholinesterase (AChE) and the natural ligand Huperzine-B and its comparison to 'AChE-Tolserine interactions'. Docking between Huperzine-B and AChE was performed using 'Autodock4.2'. Hydrophobic interactions and hydrogen bonds both play an equally important role in the correct positioning of Huperzine-B within the 'catalytic site' of AChE to permit docking. However, docking of Tolserine to AChE is largely dominated by hydrophobic interactions. Such information may aid in the design of versatile AChE-inhibitors, and is expected to aid in safe clinical use of Huperzine-B. Scope still remains in the determination of the three-dimensional structure of AChE-Huperzine-B complex by X-ray crystallography to validate the described data. Furthermore, this study confirms that Huperzine-B is a more efficient inhibitor of human brain AChE compared to tolserine with reference to K-i and Delta G values.
引用
收藏
页码:487 / 490
页数:4
相关论文
共 21 条
[1]
[Anonymous], J PSYCHOSOC NURS MEN
[2]
[Anonymous], ACETYLCHOLINESTERASE
[3]
Neurobiology of butyrylcholinesterase [J].
Darvesh, S ;
Hopkins, DA ;
Geula, C .
NATURE REVIEWS NEUROSCIENCE, 2003, 4 (02) :131-138
[4]
Goodsell D., 2013, ACETYLCHOLINESTERASE
[5]
Liu J, 1999, ACTA PHARMACOL SIN, V20, P141
[6]
Mehta Mona, 2012, Int J Alzheimers Dis, V2012, P728983, DOI 10.1155/2012/728983
[7]
Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types [J].
Munoz-Delgado, Encarnacion ;
Fernanda Montenegro, Maria ;
Javier Campoy, Francisco ;
Teresa Moral-Naranjo, Maria ;
Cabezas-Herrera, Juan ;
Kovacs, Gyula ;
Vidal, Cecilio J. .
FEBS JOURNAL, 2010, 277 (21) :4519-4529
[8]
Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors:: New disease-modifying agents for Alzheimer's disease [J].
Muñoz-Ruiz, P ;
Rubio, L ;
García-Palomero, E ;
Dorronsoro, I ;
del Monte-Millán, M ;
Valenzuela, R ;
Usán, P ;
de Austria, C ;
Bartolini, M ;
Andrisano, V ;
Bidon-Chanal, A ;
Orozco, M ;
Luque, FJ ;
Medina, M ;
Martínez, A .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (23) :7223-7233
[9]
Orhan Gurdal, 2009, Recent Pat CNS Drug Discov, V4, P43
[10]
Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase - Steps toward novel drugs for treating Alzheimer's disease [J].
Pang, YP ;
Quiram, P ;
Jelacic, T ;
Hong, F ;
Brimijoin, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (39) :23646-23649